Immunogenicity strongly impacts response to adalimumab in RA
(HealthDay)—For patients with rheumatoid arthritis (RA), long-term clinical outcomes are good with etanercept and adalimumab; but for adalimumab, treatment response is strongly dependent on the presence or absence of anti-adalimumab ...
Dec 13, 2012
0
1